Armata Pharmaceuticals, Inc. (ARMP)
NYSEAMERICAN: ARMP · Real-Time Price · USD
4.570
+0.150 (3.39%)
Aug 21, 2026, 10:43 AM EDT - Market open
Armata Pharmaceuticals Employees
Armata Pharmaceuticals had 61 employees as of December 31, 2025. The number of employees increased by 1 or 1.67% compared to the previous year.
Employees
61
Change (1Y)
1
Growth (1Y)
1.67%
Revenue / Employee
$90,869
Profits / Employee
-$3,150,459
Market Cap
169.92M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 61 | 1 | 1.67% | 61 | 0 |
| Dec 31, 2024 | 60 | -6 | -9.09% | 60 | 0 |
| Dec 31, 2023 | 66 | -9 | -12.00% | 66 | 0 |
| Dec 31, 2022 | 75 | 4 | 5.63% | 72 | 3 |
| Dec 31, 2021 | 71 | 9 | 14.52% | 69 | 2 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Humacyte | 184 |
| Codexis | 146 |
| Molecular Partners AG | 134 |
| MediWound | 121 |
| Nkarta | 106 |
| Caribou Biosciences | 97 |
| OnKure Therapeutics | 45 |
| Unicycive Therapeutics | 22 |
ARMP News
- 8 days ago - Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update - PRNewsWire
- 9 days ago - Armata Pharmaceuticals Earnings release: Q2 2026 - Filings
- 9 days ago - Armata Pharmaceuticals Quarterly report: Q2 2026 - Filings
- 22 days ago - Armata Pharmaceuticals Slides: Corporate presentation - Filings
- 4 weeks ago - Armata provides update on AP-SA02 studies - TheFly
- 4 weeks ago - Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02 - PRNewsWire
- 5 weeks ago - Armata Pharmaceuticals reaches agreement with FDA on iPSP for AP-SA02 - TheFly
- 5 weeks ago - Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus Bacteremia - PRNewsWire